PLEASANTON, Calif., Nov. 15, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its third quarter, which ended October 31, 2023, after market close on December 6, 2023. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results.
Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event.
Event: | Veeva's Fiscal 2024 Third Quarter Results Conference Call |
Date: | Wednesday, December 6, 2023 |
Time: | 2:00 p.m. PT (5:00 p.m. ET) |
Conference Call Registration: https://conferencingportals.com/event/badXudFz | |
Webcast: |
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | ||
Gunnar Hansen Veeva Systems Inc. 267-460-5839 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Maria Scurry |
Last Trade: | US$233.26 |
Daily Change: | -3.81 -1.61 |
Daily Volume: | 850,948 |
Market Cap: | US$37.870B |
January 13, 2025 December 05, 2024 November 24, 2024 November 20, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load